Design of an Ara h 2 hypoallergen from conformational epitopes.
Min, J., Keswani, T., LaHood, N.A., Lytle, I.R., Marini-Rapoport, O., Andrieux, L., Sneed, S.L., Edwards, L.L., Petrovich, R.M., Perera, L., Pomes, A., Pedersen, L.C., Patil, S.U., Mueller, G.A.(2024) Clin Exp Allergy 54: 46-55
- PubMed: 38168500 
- DOI: https://doi.org/10.1111/cea.14433
- Primary Citation of Related Structures:  
8G4P - PubMed Abstract: 
Adverse reactions are relatively common during peanut oral immunotherapy. To reduce the risk to the patient, some researchers have proposed modifying the allergen to reduce IgE reactivity, creating a putative hypoallergen. Analysis of recently cloned human IgG from patients treated with peanut immunotherapy suggested that there are three common conformational epitopes for the major peanut allergen Ara h 2. We sought to test if structural information on these epitopes could indicate mutagenesis targets for designing a hypoallergen and evaluated the reduction in IgE binding via immunochemistry and a mouse model of passive cutaneous anaphylaxis (PCA).
Organizational Affiliation: 
Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.